Population pharmacokinetics and exposure –response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias
ConclusionsVeliparib with temozolomide presents a promising combination for older patients with myeloid leukemias. An exposure –safety relationship was established for this combination. Further clinical investigations aimed at elucidating the veliparib exposure–efficacy/safety relationship and optimizing dosing recommendations for maximizing benefit–risk in patients with advanced myeloid malignancies should study veli parib doses ranging up to 120 mg in combination with temozolomide.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Leukemia | Oral Cancer | Study | Temodar | Toxicology